Reliable Endothelial Function Testing
At Our Fingertips?

David S. Celermajer, MB, BS, DSc

Noninvasive testing for the purpose of cardiovascular risk stratification has been a “holy grail” of Cardiology for some time. As the endothelium plays such a key role in normal vascular health and endothelial dysfunction is such an early event in atherogenesis, the appeal of endothelial function testing for risk stratification is easy to understand. Nevertheless, the goal of developing a noninvasive, widely applicable, reproducible, and informative test for endothelial function has so far proven elusive.

Why Endothelial Function Is Important
Although the healthy endothelium is only a monolayer of relatively simple cells that for many years was regarded as little more than a semipermeable barrier lining the vasculature, it is very well placed to exert many important homeostatic functions. The endothelium is exposed to a variety of blood-borne signals and intravascular stressors and has adapted to respond by secretion or modification of a large number of factors that regulate (inter alia) vascular tone, thromboresistance, and cellular adhesion. For example, the endothelium transduces the stimulus of increased shear stress into the response of vasorelaxation, facilitating one of the most basic cardiovascular homeostatic mechanisms of flow-mediated dilatation.

Furthermore, it transpires that some of the molecules secreted by a healthy endothelium have key functions in defense against atherosclerosis, including the important antiinflammatory and antithrombotic molecules, nitric oxide (NO) and prostacyclin. In particular, the role of NO as an agent that not only vasodilates but inhibits platelet aggregation, monocyte adhesion to endothelial cells, and abnormal smooth muscle cell proliferation has highlighted the status of NO as an important “antiatherogenic” moiety. By some serendipity, the first invasive tests (using acetylcholine as the stimulus) and the first noninvasive tests for endothelial function assessment (using shear stress as the stimulus) both result predominantly in the release of NO from the large vessels. Assessing the degree of NO-induced dilatation is thus a “barometer” for several aspects of arterial health, beyond the simple vasodilator response itself. “Endothelial dysfunction” thus defined has been used in clinical research to assess the ability of the endothelium to release NO (and by implication to protect against atherogenesis) in a variety of cross-sectional studies investigating the impact of risk factors on blood vessels and the ability of a number of potentially beneficial interventions to reverse early arterial damage.

These studies on endothelium-dependent (and also smooth muscle–dependent) vasomotor properties of the vasculature in health and disease also serve to highlight another important concept in cardiovascular pathophysiology; that vessel function may play a very important role in determining cardiovascular risk, over and above the risk conveyed by a structural impediment to flow such as a large plaque. Indeed plaque size (and minimum lumen diameter) are relatively poor predictors of cardiovascular risk, whereas vessel function (particularly the propensity for vessels to constrict rather than dilate during conditions of physical and/or mental stress) appears to confer important risk in the pathophysiology of acute vascular events. Consistent with this suggested importance of vascular function in risk determination, a large number of studies have now been published (summarized in Deanfield et al) correlating endothelial function measurements with prospectively determined risk of cardiovascular events during follow-up.

Problems With Endothelial Dysfunction: Semantic
The majority of studies examining “endothelial function” in vivo in the last decade have involved the measurement of endothelium-dependent dilatation, in large part because techniques have been developed to assess this particular aspect of endothelial physiology. The endothelium, however, has a multiplicity of functions beyond the regulation of vessel tone, as noted above. Thus, articles reporting on “endothelial function” and “dysfunction” on the basis of the measurement of endothelium-dependent dilatation give insights to only 1 aspect of endothelial physiology, albeit an important one. Little work has been done to date on how the various endothelial functions correlate with each other in disease states (for example, how impaired endothelium-dependent dilatation, regulation of endothelial cell adhesion molecule expression, and release of key hemostatic regulatory molecules relate to one another).

Problems With Endothelial Dysfunction: Biological
The above comments notwithstanding, the measurement of endothelium-dependent dilatation has given important insights into the temporal relationship between major cardiovascular risk factors and early arterial abnormalities, while providing important information in studies of reversibility. Nevertheless, the
process of endothelium-dependent dilatation is highly complex, with several putative mediators including NO, vasodilator and vasoconstrictor prostanoids (such as the potent dilator prostacyclin), and the elusive endothelium-derived hyperpolarizing factor or factors. It is almost certain that a different balance of these dilator and/or constrictor substances are of varying importance in different situations in health and disease. Regulation of vessel tone varies importantly by vessel size (for example, between epicardial arteries and myocardial resistance vessels); by site in the body (for example, between coronary and pulmonary circulation), and importantly in response to different chemical agonists. Thus, different pharmacological substances such as acetylcholine, serotonin, and bradykinin, which are widely used in endothelial function research, stimulate different amounts of vasodilator substances. Responses to these substances are themselves different from the response of vascular endothelium to the more physiological stimulus of shear stress.

Flow-Mediated Dilatation: An Appealing Test

Although the first descriptions of endothelial function measurements in humans involved measuring the response of the epicardial arteries to infused acetylcholine, such testing is clearly not applicable for either large-scale studies of endothelial function nor for use in asymptomatic subjects, particularly children and young adults at risk of atherosclerosis. Such investigations awaited the development of noninvasive endothelial function testing, which was first described in 1992. This testing involved measuring the diameter of an artery by noninvasive ultrasound before and after increasing shear stress (provided by reactive hyperemia), with the degree of dilatation reflecting (in large part) arterial endothelial NO release.

Measurement of ultrasound-based flow-mediated dilatation (FMD) in the brachial artery has intrinsic appeal, as it is noninvasive, relatively repeatable and reproducible, reflects important biology, has some data to support its predictability, and is useful in serial studies of disease reversibility (such as Woo et al). Brachial artery endothelium-dependent dilatation is also significantly correlated with findings in the coronary circulation in the same patients. Nevertheless, the measurement of FMD by ultrasound has also proven problematic for risk stratification in individuals. The method is technically demanding, requiring specific training. Furthermore, FMD is very sensitive to a number of intercurrent factors that may influence vascular function transiently but may not have great importance for long-term atherosclerosis risk. For example, FMD can be acutely lowered by an intercurrent viral illness, can be transiently impaired after a meal, and varies in a circadian pattern.

In part reflecting these difficulties, different laboratories have used different variations in technique for the measurement of FMD (for example, placing the occluding pneumatic cuff around the upper arm or lower arm) and consequently have reported different ranges of normal values of FMD. Efforts to standardize FMD technique and results have recently been published in an attempt to redress this situation. Nevertheless, the measurement of FMD by arterial ultrasound is not yet ready for "prime time" for widespread risk stratification.
the distal part of the limbs are major sites of sympathetic \( \alpha \)-adrenergic vasoconstrictor activity and hence play an important role in circulatory regulation.\(^ {13} \) It appears that endogenous NO-mediated vasoregulation is particularly prominent in the AV anastomoses in the human fingertips,\(^ {14} \) and indeed Gerhard et al have shown that approximately 60% of the RH-PAT response is mediated by NO release.\(^ {15} \)

Studies using the PAT probe have demonstrated altered endothelial function in children at cardiovascular risk because of type 1 diabetes mellitus,\(^ {16} \) have shown that impaired RH-PAT responses are present in patients with coronary microvascular endothelial dysfunction measured in vivo,\(^ {17} \) and, as in the case of Fisher et al,\(^ {18} \) have investigated reversibility of peripheral endothelial dysfunction with interventions such as flavonol-rich cocoa.

The current study reported by Hamburg et al gives further insights into the potential role of RH-PAT for the noninvasive assessment of endothelial function in asymptomatic subjects. Digital pulse amplitude was assessed in a group of nearly 2000 subjects in the Framingham Third Generation Cohort study. The authors provide important physiological information about the time dependency of the increase in fingertip pulse amplitude after reactive hyperemia and carefully document the relationship between this novel vascular measure and multiple traditional and metabolic cardiovascular risk factors, revealing a significant although relatively weak relationship between RH-PAT and most cardiovascular risk factors (r values \( \approx 0.4 \)). Some findings were counterintuitive, however, such as the lack of a significant relationship between hypertension and digital vasomotor responses and a small but paradoxically positive relation between older age and the RH-PAT. Furthermore, much of the variability in the digital pulse amplitude remained unexplained by measured clinical factors. In this cross-sectional study, Hamburg et al were also unable to investigate whether RH-PAT measurement gave any independent prognostic information, although this will be a fruitful area for further study as the subjects in this cohort are followed up.

Thus, much work remains to be done in evaluating the potential role of RH-PAT in risk stratification for individuals. Data on circadian variation, changes after meals and during intercurrent illnesses, relationship to other tests of vasomotor function known to have importance, and information about the prognostic value of this novel index above and beyond traditional risk factors require further investigation.

**Future Directions**

The noninvasive identification of subjects at higher risk of cardiovascular events than might be predicted from traditional risk factors alone is still vitally needed to facilitate effective targeted prevention. Even though none of the currently available methods for measuring endothelium-dependent dilation fulfill all the desiderata for clinical assessment of individual risk, several promising novel technologies, including RH-PAT, are being actively investigated. The measurement of endothelial function, as an integrative marker of arterial health in response to the effects of risk factors on the vessel wall, shows great promise. Nevertheless, much work remains to be done to incorporate functional assessments of nonvasomotor aspects of endothelial physiology, as well to define which testing modalities give the best readily obtainable prognostic information.

**Disclosures**

Dr Celermajer has received research support from Itamar Medical, the manufacturer of the RH-PAT device, and has participated as a speaker at Itamar-sponsored educational events.

**References**

Reliable Endothelial Function Testing: At Our Fingertips?
David S. Celermajer

Circulation. 2008;117:2428-2430
doi: 10.1161/CIRCULATIONAHA.108.775155
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/117/19/2428

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/